SG Americas Securities
QNCX icon

SG Americas Securities’s Quince Therapeutics QNCX Stock Holding History

SG Americas Securities’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-295
Closed -$78K – 3316
2022
Q3 		$78K Buy
295
+1
+0.3% +$381 ﹤0.01% 2917
2022
Q2 		$131K Buy
294
+12
+4% +$8.48K ﹤0.01% 2952
2022
Q1 		$349K Buy
+282
New +$384K ﹤0.01% 2111
2021
Q4 		– Sell
-49
Closed -$892K – 3733
2021
Q3 		$892K Buy
+49
New +$779K ﹤0.01% 2003
2021
Q2 		– Sell
-116
Closed -$838K – 3166
2021
Q1 		$838K Sell
116
-94
-45% -$676K ﹤0.01% 1668
2020
Q4 		$1.17M Sell
210
-63
-23% -$558K 0.01% 1456
2020
Q3 		$2.73M Buy
273
+79
+41% +$718K 0.02% 579
2020
Q2 		$1.79M Buy
194
+176
+978% +$1.61M 0.01% 908
2020
Q1 		$168K Buy
+18
New +$178K ﹤0.01% 2632

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

SG Americas Securities's QNCX Position: Q4 2022 in Review

SG Americas Securities sold out of Quince Therapeutics (QNCX) in Q4 2022, closing a stake of 295 shares — an estimated $78K sold.

SG Americas Securities first reported a position in QNCX in Q1 2020 and held it in 9 quarters. The position peaked at $2.73M in Q3 2020. 48 funds tracked by Wall St. Rank hold QNCX as of Q4 2022.

  • SG Americas Securities reported no remaining Quince Therapeutics position as of Q4 2022 after selling out during the quarter.
  • SG Americas Securities sold 295 Quince Therapeutics shares in Q4 2022, an estimated $78K.
  • SG Americas Securities first reported a position in Quince Therapeutics in Q1 2020 and held it in 9 quarters.
  • SG Americas Securities's Quince Therapeutics position peaked at $2.73M in Q3 2020.
  • 48 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2022.

Based on SG Americas Securities's 13F filing for Q4 2022, filed 2 Feb 2023.